Follistatin‐like protein 5 inhibits hepatocellular carcinoma progression by inducing caspase‐dependent apoptosis and regulating Bcl‐2 family proteins. Issue 12 (25th September 2018)
- Record Type:
- Journal Article
- Title:
- Follistatin‐like protein 5 inhibits hepatocellular carcinoma progression by inducing caspase‐dependent apoptosis and regulating Bcl‐2 family proteins. Issue 12 (25th September 2018)
- Main Title:
- Follistatin‐like protein 5 inhibits hepatocellular carcinoma progression by inducing caspase‐dependent apoptosis and regulating Bcl‐2 family proteins
- Authors:
- Li, Chunlei
Dai, Lei
Zhang, Junfeng
Zhang, Yujing
Lin, Yi
Cheng, Lin
Tian, Hongwei
Zhang, Xin
Wang, Qingnan
Yang, Qianmei
Wang, Yuan
Shi, Gang
Cheng, Fuyi
Su, Xiaolan
Yang, Yang
Zhang, Shuang
Yu, Dechao
Wei, Yuquan
Deng, Hongxin - Abstract:
- Abstract: Hepatocellular carcinoma (HCC) is one of the most common and deadly malignant tumors in the world, especially in China. Follistatin‐like protein 5 (FSTL5) is a member of the FSTL family, which is involved in cell proliferation, migration, differentiation, and embryo development. We aimed to investigate the function and underlying mechanism of FSTL5 in HCC. FSTL5 expression was determined by immunohistochemistry staining in a liver cancer tissue microarray (TMA) and the correlation between FSTL5 and the prognosis of HCC patients was analysed. Further proliferation assay, colony formation assay, flow cytometry, and xenograft tumor model were performed to investigate the bioeffects of FSTL5 in HCC in vitro and in vivo. We found that FSTL5 expression was downregulated in HCC tissues and positively correlated with the prognosis of patients with HCC at tumor node metastasis stage I/II. Overexpression of FSTL5 efficiently impaired HCC growth both in vivo and in vitro with an exogenous manner. Mechanistic investigation demonstrated that FSTL5 promoted HCC cell apoptosis in a caspase‐dependent manner and regulated Bcl‐2 family proteins. These results indicate that FSTL5 may be a potential novel target for HCC treatment, and a biomarker for tumor prognosis.
- Is Part Of:
- Journal of cellular and molecular medicine. Volume 22:Issue 12(2018)
- Journal:
- Journal of cellular and molecular medicine
- Issue:
- Volume 22:Issue 12(2018)
- Issue Display:
- Volume 22, Issue 12 (2018)
- Year:
- 2018
- Volume:
- 22
- Issue:
- 12
- Issue Sort Value:
- 2018-0022-0012-0000
- Page Start:
- 6190
- Page End:
- 6201
- Publication Date:
- 2018-09-25
- Subjects:
- apoptosis -- Bcl‐2 family proteins -- caspase -- FSTL5
Cytology
Medicine
Molecular Biology
Cytologie -- Périodiques
Médecine -- Périodiques
Biologie moléculaire -- Périodiques
Cytology -- Periodicals
Medicine -- Periodicals
Molecular biology -- Periodicals
611.01805 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1582-4934 ↗
http://www.blackwell-synergy.com/loi/jcmm ↗
http://www.usc.edu/hsc/nml/e-resources/info/joucelmm.html ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/jcmm.13906 ↗
- Languages:
- English
- ISSNs:
- 1582-1838
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4955.005000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 8618.xml